Market Cap : 4.11 B | Enterprise Value : 4.71 B | PE Ratio : At Loss | PB Ratio : 7.92 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Guardant Health's Operating Income for the three months ended in Mar. 2022 was $-123.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-426.5 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Guardant Health's Operating Income for the three months ended in Mar. 2022 was $-123.3 Mil. Guardant Health's Revenue for the three months ended in Mar. 2022 was $96.1 Mil. Therefore, Guardant Health's Operating Margin % for the quarter that ended in Mar. 2022 was -128.34%.
Good Sign:
Guardant Health Inc operating margin is expanding. Margin expansion is usually a good sign.
Guardant Health's 5-Year average Growth Rate for Operating Margin % was 13.10% per year.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guardant Health's annualized ROC % for the quarter that ended in Mar. 2022 was -40.89%. Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -150.02%.
The historical data trend for Guardant Health's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-426.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Guardant Health's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:
ROC % (Q: Mar. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2021 ) | + | Invested Capital (Q: Mar. 2022 )) | / count ) |
= | -493.352 * ( 1 - 0.02% ) | / | ( (1235.051 | + | 1177.602) | / 2 ) |
= | -493.2533296 | / | 1206.3265 | |||
= | -40.89 % |
where
Invested Capital | (Q: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 2204.499 | - | 50.009 | - | ( 932.748 | - | max(0, 194.687 | - | 1114.126 | + | 932.748 | )) |
= | 1235.051 |
Invested Capital | (Q: Mar. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 2129.598 | - | 67.525 | - | ( 962.266 | - | max(0, 228.809 | - | 1113.28 | + | 962.266 | )) |
= | 1177.602 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.
2. Joel Greenblatt's definition of Return on Capital:
Guardant Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:
ROC (Joel Greenblatt) % | (Q: Mar. 2022 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Dec. 2021 | Q: Mar. 2022 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -490.432 | / | ( ( (313.904 + max(-0.4530000000001, 0)) | + | (339.929 + max(-61.239, 0)) ) | / | 2 ) |
= | -490.432 | / | ( ( 313.904 | + | 339.929 ) | / | 2 ) |
= | -490.432 | / | 326.9165 | ||||
= | -150.02 % |
where Working Capital is:
Working Capital | (Q: Dec. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (97.652 | + | 30.674 | + | 53.052) | - | (50.009 | + | 11.326 | + | 120.496) |
= | -0.4530000000001 |
Working Capital | (Q: Mar. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (84.331 | + | 36.613 | + | 30.07) | - | (67.525 | + | 10.57 | + | 134.158) |
= | -61.239 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.
3. Operating Income is also linked to Operating Margin %:
Guardant Health's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) |
= | -123.338 | / | 96.099 | |
= | -128.34 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Guardant Health's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By tipranks.com 2022-03-10
By Fool 2022-03-08
By tipranks.com 2022-02-16
By Zacks 2021-07-30
By Zacks 2022-02-01
By Zacks 2022-01-27
By Zacks 2021-11-03
By tipranks.com 2022-03-05
By Zacks 2021-07-19
By Fool 2022-01-12
By Fool 2022-04-01
By Seekingalpha 2021-11-04
By Zacks 2022-02-23